Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm

This article outlines novel targeted approaches that are in preclinical or clinical development for BPDCN. Although there is no known targetable genetic abnormality that defines BPDCN, data from functional testing of primary tumors, gene expression analyses, and adaptation of targeted drug approaches from other cancers to BPDCNs harboring specific mutations have nominated several promising strategies.

Source: Hematology/Oncology Clinics of North America - March 17, 2020 Category: Cancer & Oncology Authors: Andrew A. Lane Source Type: research